Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12

NCT00052377 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00052377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00052377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2002
Completion date
Not reported
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent mycosis fungoides/sezary syndrome, stage i cutaneous t-cell non-hodgkin lymphoma, stage i mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage ii mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv mycosis fungoides/sezary syndrome